05:33 AM EDT, 07/28/2025 (MT Newswires) -- Biogen's (BIIB) tofersen, or Qalsody, has received approval from the UK's Medicines and Healthcare Products Regulatory Agency to treat adults with amyotrophic lateral sclerosis associated with a mutation in the superoxide dismutase 1 gene, the agency said Monday.

Amyotrophic lateral sclerosis is a progressive condition that impacts nerve cells in the brain and spinal cord.